Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication

Hepatology

Volumn 29, Issue 4, 1999, Pages 1262-1271

  Polyak, Stephen J ^a,c   Paschal, Denise M ^a   McArdle, Susan ^a   Gale, Michael J ^a   Moradpour, Darius ^b   Gretch, David R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Annex Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS NONSTRUCTURAL 5A PROTEIN; INTERFERON; TETRACYCLINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DELETION MUTANT; DRUG RESISTANCE; ENCEPHALOMYOCARDITIS VIRUS; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HELA CELL; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

EID: 0032899696     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290438     Document Type: Article

References (13)

1. Rice CM. Flaviviridae: the viruses and their replication. In: Fields DMKBN, Howley PM, eds. Fields Virology, ed 3. Philadelphia: Lippincott-Raven, 1996:931-960.
2. Reed KE, Gorbalenya AE, Rice CM. The NS5A/NS5 proteins of viruses from three genera of ihe family Flaviviridae are phosphorylated by associated serine/threonine kinases. J Virol 1998;72:6199-6206.
3. Alter HJ. To C or not to C: these are the questions. Blood 1995;85:1681-1695.
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
5. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. HEPATOLOGY 1997;26:2S-10S.
6. Davis GL, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-1506.
7. Di Bisceglie AM, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
8. Lindsay KL. Therapy of hepatitis C: overview. HEPATOLOGY 1997;26:71S-77S.
9. Carithers RLJ, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. HEPATOLOGY 1997;26:83S-88S.
10. Keeffe EB, Hollinger FB, a.t.C.I.S. Group. Therapy of hepatitis C: consensus interferon trials. HEPATOLOGY 1997; S1
11. Mita E, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994;39:977-982.
12. Tsubota A, et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 1993;8:535-539.
13. Yoshioka K, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. HEPATOLOGY 1992;16:293-299.